Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Olanzapine versus haloperidol in children with autistic disorder: An open pilot study
Autore:
Malone, RP; Cater, J; Sheikh, RM; Choudhury, MS; Delaney, MA;
Indirizzi:
Med Coll Penn & Hahnemann Univ, Eastern Penn Psychiat Inst, Dept Psychiat,Philadelphia, PA 19129 USA Med Coll Penn & Hahnemann Univ Philadelphia PA USA 19129 ia, PA 19129 USA Biomet Stat Consulting, Wynnewood, PA USA Biomet Stat Consulting Wynnewood PA USA at Consulting, Wynnewood, PA USA Temple Univ, Philadelphia, PA 19122 USA Temple Univ Philadelphia PA USA 19122 le Univ, Philadelphia, PA 19122 USA
Titolo Testata:
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
fascicolo: 8, volume: 40, anno: 2001,
pagine: 887 - 894
SICI:
0890-8567(200108)40:8<887:OVHICW>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERVASIVE DEVELOPMENTAL DISORDERS; DOUBLE-BLIND; BEHAVIORAL SYMPTOMS; INFANTILE-AUTISM; TARDIVE-DYSKINESIA; YOUNG-CHILDREN; LONG-TERM; RISPERIDONE; TRIAL; ADOLESCENTS;
Keywords:
autistic disorder; neuroleptic drug treatment;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
55
Recensione:
Indirizzi per estratti:
Indirizzo: Malone, RP Med Coll Penn & Hahnemann Univ, Eastern Penn Psychiat Inst, Dept Psychiat,3200 Henry Ave, Philadelphia, PA 19129 USA Med Coll Penn & Hahnemann Univ 3200 Henry Ave Philadelphia PA USA 19129
Citazione:
R.P. Malone et al., "Olanzapine versus haloperidol in children with autistic disorder: An open pilot study", J AM A CHIL, 40(8), 2001, pp. 887-894

Abstract

Objectives: Conventional neuroleptics ameliorate symptoms in children withautistic disorder; however, they are known to cause dyskinesias. Atypical neuroleptics, including olanzapine, may have less risk for dyskinesia, but their efficacy in autistic disorder is not established. This study was designed to investigate the safety and effectiveness of open-label olanzapine as a treatment for children with autistic disorder by using haloperidol as astandard comparator treatment. Method: In a parallel groups design, 12 children with DSM-I autistic disorder (mean age 7.8 +/- 2.1 years) were randomized to 6 weeks of open treatment with olanzapine or haloperidol. Mean final dosages were 7.9 +/- 2.5 mg/day for olanzapine and 1.4 +/- 0.7 mg/day forhaloperidol. Outcome measures included the Clinical Global Impressions (CGI) and the Children's Psychiatric Rating Scale (CPRS). Results: Both groupshad symptom reduction. Five of six in the olanzapine group and three of six in the haloperidol group were rated as responders according to the CGI Improvement item. Subjects showed improvement on the CPRS Autism Factor (F-1,F-9 = 24.4, p = .0008). Side effects included drowsiness and weight gain. Conclusions: The findings suggest that olanzapine is a promising treatment for children with autistic disorder. Further placebo-controlled and long-term studies of olanzapine in autistic disorder are required.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 13:01:18